Breaking Research News from sources other than Breastcancer.org

marijen

Optimal Duration of Adjuvant Endocrine Therapy Undecided in ER+ Breast Cancer

Caroline Seymour

Published: Tuesday, Jul 10, 2018

Www.onclive.com

Under breast cance

marijen

Optimal Use With Adjuvant Endocrine Therapy Continues to Unfold in ER+ Breast Cancer

Caroline Seymour

Published: Monday, Jul 09, 2018

Excerpt

"You're treating 20 to 30 patients with a drug for 10 years to help one patient," said Denes. "We have to figure out how to better identify that one patient and let the other patients live happy lives."

Www.onclive.com

marijen

FDA recalls heart drugs made by Teva, others over carcinogen impurity

By Wallace Witkowski

Published: July 13, 2018 5:58 p.m. ET

https://www.marketwatch.com/story/fda-recalls-heart-drugs-made-by-teva-others-over-carcinogen-impurity-2018-07-13

KPW3

Antibody-Drug Conjugate Gets Priority Review for Metastatic Triple-Negative Breast Cancer

https://www.empr.com/drugs-in-the-pipeline/sacituz...

KPW3

FDA Approves Additional Breast Cancer Indications for Kisqali

https://www.empr.com/news/kisqali-ribociclib-preme...

Heidihill

marjen, I was on AIs.

marijen

This article explains how cancer treatment promotes cancer growth

Killing cancer softly: New approach halts tumor growth

Published Friday 1 December 2017

By Ana Sandoiu

Fact checked by Jasmin Collier

https://www.medicalnewstoday.com/articles/320227.p...

brigid_TO

Compared with subjects sleeping immediately after supper, those sleeping two or more hours after supper had a 20% reduction in cancer risk for breast and prostate cancer. A similar protection was observed in subjects having supper before 9 pm compared with supper after 10 pm,

Effect of mistimed eating patterns on breast and prostate cancer risk (MCC‐Spain Study)

marijen

Breast Cancer Trials

https://www.breastcancertrials.org/BCTIncludes/Avo...

marijen

Check here to see if your doctor receives payments from drug companies.

https://openpaymentsdata.cms.gov/

marijen

Doctors Give Patients 11 Seconds to Explain Reason for Visit

https://www.studyfinds.org/doctors-give-patients-1...

marijen

Here's the skinny:

The study, published by JAMA Internal Medicine, evaluated nearly 1.6 million elderly Medicare holders hospitalized from Jan. 1, 2011 to Dec. 31, 2014. It determined that patients treated by female doctors had significantly lower rates of death and significantly lower rates of readmission to the hospital than patients who were treated by male doctors at the same hospital.

Lumpie

I haven't been on in a while due to my very crazy schedule.

I saw the discussion about California labeling regarding substances "known to the State of California to cause cancer or reproductive toxicity." We've (almost) all seen these on nationally marketed products and the signs are ubiquitous in California. For many years, I have wondered, is California the only one demanding meaningful labeling or have they gone way overboard? The contrast of silence from all other quarters vs the abundance of labeling in California is jarring. It's hard to know where to start, but for those interested in reading more on the topic, here's a link to the American Cancer Society's briefing on the subject. https://www.cancer.org/cancer/cancer-causes/genera...

For those looking for additional perspectives, the organization Breast Cancer Action seems to be active in raising concerns related to environmental issues as possible causes of cancer. There is also a book on the topic, No Family History, by Sabrina McCormick. Not sure whether there is a forum on BC.org on the topic....?

Lumpie

Safety by Body Weight of Adjuvant Subcutaneous Trastuzumab for HER2+ Early Breast Cancer

https://www.practiceupdate.com/C/71137/56?elsca1=e...

• This is a report of subgroup analyses of the SafeHer trial, evaluating the safety by body weight of fixed-dose subcutaneous trastuzumab as adjuvant treatment for early-stage, HER2-positive breast cancer.
• The safety profile was consistent across subgroups of body weight and the overall patient population, including those with lowest body weight and those of Asian origin.

I was thrilled to see that further study is being done on Subcutaneous Trastuzumab for HER2+ Breast Cancer. Alas, none of the study centers is in the U.S. (We need access to this mode of therapy in the states!) The link to clinical trial info is:

https://clinicaltrials.gov/ct2/show/NCT01566721

marijen

Toxins and the Immune system

300,000 new chemicals are listed each year! How can that be?

http://www.immunesystemetc.com/Toxins.html

Warrior2018

That is very disturbing Marijen. I can’t believe the amount of toxins that exists!!! Ugh!

marijen

Warrior it just impossible to avoid all the chemicals. I give up

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline: Journal of Clinical Oncology: Vol 35, No 18

http://ascopubs.org/doi/10.1200/JCO.2016.70.7257

7of9

Marijen, Thank you...I go for my 5th Zometa infusion next Friday (every 6 months).

MinusTwo

I've just had my 5th Prolia injection - also every 6 months.

marijen

So 7of9 and Minus Two, you are getting these treatments as preventative? I had three yearly reclast, two before BC dx and 1 after. Don’t know why but my endocrinologist won’t give me more. I thought they made me feel better in the bones and muscles. Osteoporosis.

marijen

Estrogen regulates the brain's fear response, protecting against PTSD

https://www.medicalnewstoday.com/articles/315383.p...

MinusTwo

marijen - no I had osteoporosis from the treatments. I sent you a PM.

7of9

yes, mine are preventative though diagnosed with mild osteo

Anonymous

I know the value of estrogen re: regulating emotions, but I'm glad to have this article. At least I know my abject fear about everything at times, and my recurrent PTSD, isn't simply a character flaw.

Anonymous

I know the value of estrogen re: regulating emotions, but I'm glad to have this article about estrogen and PTSD. At least I know my abject fear about everything at times, and my recurrent PTSD, isn't simply a character flaw.

marijen

FDA Approves Magnetic Localization System for Lymph Node Biopsy in Breast Cancer

https://www.onclive.com/web-exclusives/fda-approve...

Lumpie

Association of Circulating Tumor Cells With Late Recurrence of ER+ Breast Cancer

https://www.practiceupdate.com/C/71320/56?elsca1=e...

• In this secondary analysis of a randomized clinical trial, circulating tumor cells were detectable in 26 of 547 patients (4.8%) with localized breast cancer 5 or more years after diagnosis. Circulating tumor cells were also associated with a higher risk of recurrence among patients with hormone receptor–positive breast cancer.
• Circulating tumor cells may be used to stratify for risk of late recurrence among patients with hormone receptor–positive breast cancer.

Lumpie

Psychosocial Outcomes of Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer

https://www.practiceupdate.com/C/71318/56?elsca1=e...

• This study prospectively examined psychosocial outcomes before and up to 18 months after surgery in women with nonhereditary breast cancer who did and did not have contralateral prophylactic mastectomy (CPM). A total of 288 women provided questionnaire data, of whom 50 underwent CPM. Before surgery, women who subsequently received CPM had higher cancer distress, cancer worry, and body image concerns than women who did not have CPM. Quality of life was similar between the two groups before surgery but declined 1 month after surgery and remained lower in women who underwent CPM.
• These results may facilitate informed discussions between women and their physicians regarding CPM. Fear and worry may be foremost concerns at the time surgical decisions are made, when women may not anticipate the adverse future effect of CPM on body image and quality of life.

Lumpie

Impact of the Second Reader on Screening Outcomes at Blinded Double Reading of Digital Screening Mammograms

https://www.practiceupdate.com/C/71423/56?elsca1=e...

• This prospective study compared outcomes of blinded double vs single readings of screening mammograms on detection rates of breast cancer.
• The second reader program increased the cancer detection rate, but also increased the recall rate and false-positive rate.

Lumpie

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.

https://www.ncbi.nlm.nih.gov/pubmed/27669438

Abstract

The CXCR4 receptor and its ligand CXCL12 (also named stromal cell-derived factor 1, SDF1) have a critical role in chemotaxis and homing, key steps in cancer metastasis. Although myofibroblasts expressing CXCL12 are associated with the presence of axillary metastases in HER2 breast cancers (BC), the therapeutic interest of targeting CXCR4/CXCL12 axis in the different BC subtypes remains unclear. Here, we investigate this question by testing antitumor activity of CXCR4 inhibitors in patient-derived xenografts (PDX), which faithfully reproduce human tumor properties. We observed that two CXCR4 inhibitors, AMD3100 and TN14003, efficiently impair tumor growth and metastasis dissemination in both Herceptin-sensitive and Herceptin-resistant HER2 BC. Conversely, blocking CXCR4/CXCL12 pathway in triple-negative (TN) BC does not reduce tumor growth, and can even increase metastatic spread. Moreover, although CXCR4 inhibitors significantly reduce myofibroblast content in all BC subtypes, they decrease angiogenesis only in HER2 BC. Thus, our findings suggest that targeting CXCR4 could provide some therapeutic interest for HER2 BC patients, whereas it has no impact or could even be detrimental for TN BC patients.

PMID: 27669438 PMCID: PMC5340801 DOI: 10.1038/onc.2016.284